177 related articles for article (PubMed ID: 30815697)
1. Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity.
Sobh A; Loguinov A; Yazici GN; Zeidan RS; Tagmount A; Hejazi NS; Hubbard AE; Zhang L; Vulpe CD
Toxicol Sci; 2019 May; 169(1):108-121. PubMed ID: 30815697
[TBL] [Abstract][Full Text] [Related]
2. Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo.
Wahiduzzaman M; Ota A; Karnan S; Hanamura I; Mizuno S; Kanasugi J; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Takami A; Hosokawa Y
Cancer Lett; 2018 Oct; 433():117-130. PubMed ID: 29944906
[TBL] [Abstract][Full Text] [Related]
3. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H
Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
5. Smart Human-Serum-Albumin-As
Peng Y; Zhao Z; Liu T; Li X; Hu X; Wei X; Zhang X; Tan W
Angew Chem Int Ed Engl; 2017 Aug; 56(36):10845-10849. PubMed ID: 28686804
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
[TBL] [Abstract][Full Text] [Related]
7. Cellular and molecular alterations induced by low‑dose fisetin in human chronic myeloid leukemia cells.
Klimaszewska-Wiśniewska A; Grzanka D; Czajkowska P; Hałas-Wiśniewska M; Durślewicz J; Antosik P; Grzanka A; Gagat M
Int J Oncol; 2019 Dec; 55(6):1261-1274. PubMed ID: 31638196
[TBL] [Abstract][Full Text] [Related]
8. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
9. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
[TBL] [Abstract][Full Text] [Related]
10. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
12. Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
Luo Z; Gao M; Huang N; Wang X; Yang Z; Yang H; Huang Z; Feng W
J Exp Clin Cancer Res; 2019 May; 38(1):224. PubMed ID: 31138265
[TBL] [Abstract][Full Text] [Related]
13. Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells.
Hayatigolkhatmi K; Padroni G; Su W; Fang L; Gómez-Castañeda E; Hsieh YC; Jackson L; Holyoake TL; Pellicano F; Burley GA; Jørgensen HG
Blood Cells Mol Dis; 2018 Mar; 69():119-122. PubMed ID: 29217295
[No Abstract] [Full Text] [Related]
14. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
15. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
16. Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line.
Guo-Bao W; Xiao-Qin C; Qi-Rong G; Jie L; Gui-Nan L; Yue L
Leuk Lymphoma; 2010 Jun; 51(6):1090-7. PubMed ID: 20470221
[TBL] [Abstract][Full Text] [Related]
17. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
18. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
Holtz MS; Forman SJ; Bhatia R
Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728
[TBL] [Abstract][Full Text] [Related]
19. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Wong SM; Liu FH; Lee YL; Huang HM
PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
[TBL] [Abstract][Full Text] [Related]
20. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
